Table 4.
Represents the changes in the comet cell generation, comet tail length, ovarian follicles, and uterine histopathology following NAC co-administration in different doses. Data represent mean ± SE, N = 6, ANOVA followed by post hoc Dunnett t-test, *p < 0.05, **p < 0.01, ***p < 0.001.
| Control | As3+ | As3+ NAC 50 mg | As3+ NAC 100 mg | |
|---|---|---|---|---|
| Comet in number | 0.83 ± 0.3 | 5.83 ± 0.6*** | 2.5 ± 0.4* | 1.66 ± 0.4 |
| Comet tail length (μm) | 22.33 ± 1.11 | 39.37 ± 2.33*** | 23.51 ± 0.97 | 21.7 ± 1.05 |
| SPAF | 9.66 ± 1.05 | 2.16 ± 0.6*** | 5.83 ± 0.98* | 7.66 ± 0.84 |
| LPAF | 8.5 ± 0.8 | 1.5 ± 0.22*** | 4.83 ± 0.54* | 7.66 ± 1.28 |
| SAF | 6.16 ± 0.79 | 1.33 ± 0.21*** | 2.66 ± 0.4*** | 2.83 ± 0.4*** |
| MAF | 3.00 ± 0.25 | 1.33 ± 0.33* | 2.00 ± 0.63 | 2.33 ± 0.42 |
| LAF | 1.33 ± 0.21 | 1.00 ± 0.36 | 1.83 ± 0.3 | 2.16 ± 0.3 |
| GF | 2.16 ± 0.3 | 1.00 ± 0.25* | 1.5 ± 0.22 | 2.16 ± 0.3 |
| ATF | 1.33 ± 0.6 | 15.33 ± 2.29*** | 1.66 ± 0.4 | 2.66 ± 0.8 |
| Endometrium (μm) | 290.3 ± 8.88 | 115.31 ± 6.29*** | 185.82 ± 5.08*** | 196.39 ± 2.49*** |
| Myometrium (μm) | 108.6 ± 1.66 | 64.47 ± 2.87*** | 90.49 ± 3.65** | 91.72 ± 2.88** |